Three-Dimensional Power Doppler Ultrasound Improves the Diagnostic Accuracy for Ovarian Cancer Prediction

Cohen, Lionel; Escobar, Pedro F.; Scharm, Carol; Glimco, Beth; Fishman, David A.

doi:10.1006/gyno.2001.6253

Cited by 191 publications

(122 citation statements)

References 27 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Various second-line tests have been explored to reduce the false-positive rate and facilitate discrimination between benign and malignant ovarian lesions. These include CA125 (44), multiple serum tumor markers, computerized tomography and magnetic resonance imaging (45), and newer modalities like three-dimensional ultrasound and three-dimensional power Doppler (46,47). Self-teaching computer models such as neural networks that may increase the reproducibility of results are being investigated in order to address the problem of the subjectivity of ultrasound (48 -50).…”

Section: Ovx1mentioning

confidence: 99%

“…Even when Doppler examinations were simplified and limited to the expression of internal color flow, grayscale sonography was a more sensitive indicator of malignancy than Doppler sonography (57). Recently, some studies have shown that three-dimensional power Doppler examinations may be more accurate than two-dimensional Doppler examinations (46). However, other experts dispute this (59).…”

Section: Ovx1mentioning

confidence: 99%

See 1 more Smart Citation

Progress and Challenges in Screening for Early Detection of Ovarian Cancer

Jacobs

Menon

2004

Molecular & Cellular Proteomics

421

312

View full text Add to dashboard Cite

Ovarian cancer is characterize by few early symptoms, presentation at an advanced stage, and poor survival. As a result, it is the most frequent cause of death from gynecological cancer. During the last decade, a research effort has been directed toward improving outcomes for ovarian cancer by screening for preclinical, early stage disease using both imaging techniques and serum markers. Numerous biomarkers have shown potential in samples from clinically diagnosed ovarian cancer patients, but few have been thoroughly assessed in preclinical disease and screening. The most thoroughly investigated biomarker in ovarian cancer screening is CA125. Prospective studies have demonstrated that both CA125 and transvaginal ultrasound can detect a significant proportion of preclinical ovarian cancers, and refinements in interpretation of results have improved sensitivity and reduced the false-positive rate of screening. There is preliminary evidence that screening can improve survival, but the impact of screening on mortality from ovarian cancer is still unclear. Prospective studies of screening are in progress in both the general population and high-risk population, including the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKC-TOCS), a randomized trial involving 200,000 postmenopausal women designed to document the impact of screening on mortality. Recent advances in technology for the study of the serum proteome offer exciting opportunities for the identification of novel biomarkers or patterns of markers that will have greater sensitivity and lead time for preclinical disease than CA125. Considerable interest and controversy has been generated by initial results utilizing surface-enhanced laser desorption/ionization (SELDI) in ovarian cancer. There are challenging issues related to the design of studies to evaluate SELDI and other proteomic technology, as well as the reproducibility, sensitivity, and specificity of this new technology. Large serum banks such as that assembled in UKCTOCS, which contain preclinical samples from patients who later developed ovarian cancer and other disorders, provide a unique resource for carefully designed studies of proteomic technology. There is a sound basis for optimism that further developments in serum proteomic analysis will provide powerful methods for screening in ovarian cancer and many other diseases.

show abstract

Section: Ovx1mentioning

confidence: 99%

Section: Ovx1mentioning

confidence: 99%

Progress and Challenges in Screening for Early Detection of Ovarian Cancer

Jacobs

Menon

2004

Molecular & Cellular Proteomics

421

312

View full text Add to dashboard Cite

show abstract

“…3,4 CA125, apolipoprotein A1, transthyretin, inter-a trypsin inhibitor heavychain H4, haptoglobin-1 and kallikrein have been proposed as markers of ovarian cancer. [5][6][7][8] However, none of the identified protein markers has been found to predict cancer appearance and development with a probability value close to 100%. This can be explained by the presence of these proteins in normal nontransformed cells as well as in tumor cells; in tumors, marker proteins change their activities or relocalize in cells.…”

mentioning

confidence: 99%

Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients

et al. 2006

View full text Add to dashboard Cite

Plasma samples of ovarian and breast cancer patients were used to search for markers of cancer using 2-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time of flight mass spectrometry. Truncated forms of cytosolic serine hydroxymethyl transferase (cSHMT), T-box transcription factor 3 (Tbx3) and utrophin were aberrantly expressed in samples from cancer patients as compared to samples from noncancerous cases. Aberrant expression of proteins was validated by immunoblotting of plasma samples with specific antibodies to cSHMT, Tbx3 and utrophin. A cohort of 79 breast and 39 ovarian cancer patients and 31 individuals with noncancerous conditions was studied. We observed increased expression of truncated cSHMT, Tbx3 and utrophin in plasma samples obtained from patients at early stages of disease. Our data suggest that cSHMT, Tbx3 and utrophin can be used as components of multiparameter monitoring of ovarian and breast cancer (supplementary material for this article can be found on the International Journal of Cancer website at

show abstract

“…One of them found 3D power Doppler to improve sensitivity and specificity with regard to malignancy [122], the other did not [123]. The possibility to use ultrasound contrast for evaluating adnexal masses has been discussed in two publications [124,125], but there are not yet any published studies describing the clinical usefulness of using ultrasound contrast.…”

Section: Palpable Pelvic Massmentioning

confidence: 99%

Imaging in gynecology

Valentin

2006

Best Practice & Research Clinical Obstetrics & Gynaecol

View full text Add to dashboard Cite

This chapter summarizes the diagnostic performance (sensitivity, specificity, positive and negative likelihood ratios) of ultrasound, computer tomography, and magnetic resonance imaging in the diagnosis of various gynecological diseases and tumors. Positron emission tomography is not discussed. Imaging in infertility, in the diagnosis of Mullerian duct anomalies and in gynecological oncology (staging of gynecological cancers, diagnosis of recurrence of gynecological cancer, diagnosis of trophoblastic tumors) is not dealt with.Ultrasound is the first line imaging method for discrimination between viable intrauterine pregnancy, miscarriage and tubal pregnancy in women with bleeding and/or pain in early pregnancy, for discrimination between benign and malignant adnexal masses and for making a specific diagnosis in adnexal tumors (e.g., dermoid cyst, endometrioma, hemaorrhagic corpus luteum, ectetera), for diagnosing intracavitary uterine pathology in women with bleeding problems, and for confirming or refuting pelvic pathology in women with pelvic pain. Magnetic resonance imaging may have a role as a secondary test in the diagnosis of adenomyosis, 'deep endometriosis' (e.g., endometriosis in the rectovaginal septum or in the utero-sacral ligaments), and in the diagnosis of extremely rare types of ectopic pregnancy (e.g., in the spleen, liver or retroperitoneum).

show abstract

Three-Dimensional Power Doppler Ultrasound Improves the Diagnostic Accuracy for Ovarian Cancer Prediction

Cited by 191 publications

References 27 publications

Progress and Challenges in Screening for Early Detection of Ovarian Cancer

Progress and Challenges in Screening for Early Detection of Ovarian Cancer

Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients

Imaging in gynecology

Contact Info

Product

Resources

About